Activation of nuclear factor kappa B inflammatory bowel disease. - Test2 - elhamkhani - TriplyDB

Activation of nuclear factor kappa B inflammatory bowel disease.

Activation of nuclear factor kappa B inflammatory bowel disease.

http://www.wikidata.org/entity/Q35350256

about

Phosphodiesterase 4-targeted treatments for autoimmune diseases A review of the efficacy of traditional Iranian medicine for inflammatory bowel disease Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*)Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1beta generation Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays Nanomedicine and drug delivery strategies for treatment of inflammatory bowel disease Molecular profile of colorectal cancer in Indonesia: is there another pathway?Chemopreventive drugs: mechanisms via inhibition of cancer stem cells in colorectal cancer Tnfa signaling through tnfr2 protects skin against oxidative stress-induced inflammation Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data Particulate matter air pollution causes oxidant-mediated increase in gut permeability in mice Functional metagenomics: a high throughput screening method to decipher microbiota-driven NF-κB modulation in the human gut Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes.Therapeutic effect of intracolonically administered nuclear factor kappa B (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis.Functional genomics in gastroenterology Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis.Dysregulation of human beta-defensin-2 protein in inflammatory bowel disease.Neurotrophins regulate bone marrow stromal cell IL-6 expression through the MAPK pathway Transcriptional and Molecular Pathways Activated in Mesenteric Adipose Tissue and Intestinal Mucosa of Crohn's Disease Patients.Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: Results from a randomized double blind placebo controlled trial The clinical Pseudomonas fluorescens MFN1032 strain exerts a cytotoxic effect on epithelial intestinal cells and induces Interleukin-8 via the AP-1 signaling pathway.Defective apoptosis in intestinal and mesenteric adipose tissue of Crohn's disease patients Ron receptor signaling is protective against DSS-induced colitis in mice.SLCO3A1, A novel crohn's disease-associated gene, regulates nf-κB activity and associates with intestinal perforation Review article: the role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases.Prevalence of SLC22A4, SLC22A5 and CARD15 gene mutations in Hungarian pediatric patients with Crohn's disease.Genetic deletion of Klf4 in the mouse intestinal epithelium ameliorates dextran sodium sulfate-induced colitis by modulating the NF-κB pathway inflammatory response Nuclear factor-kappa B decoy suppresses nerve injury and improves mechanical allodynia and thermal hyperalgesia in a rat lumbar disc herniation model.LITAF mediation of increased TNF-α secretion from inflamed colonic lamina propria macrophages.Alternative medicines as emerging therapies for inflammatory bowel diseases.Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides.Evaluation of the effect of pyrrolidine dithiocarbamate in suppressing inflammation in mice with dextran sodium sulfate-induced colitis Manipulation of cytokines in the management of patients with inflammatory bowel disease.Tribbles 2 (Trib2) is a novel regulator of toll-like receptor 5 signaling Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease.NCX-1015, a nitric-oxide derivative of prednisolone, enhances regulatory T cells in the lamina propria and protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice.Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature.Effects of baicalin in CD4 + CD29 + T cell subsets of ulcerative colitis patients.

P2860

Q21245284-D4A3285E-31C0-43FA-B765-487D276FE8E8 Q24601108-D0D85DEF-7DA3-4755-BDAA-7FD0E1887F54 Q24631660-7509F90E-8FA2-4D28-81A7-38DC8734430B Q24669692-6613C60A-5F65-4526-9555-3F512A80A7E4 Q24683293-7564EBDC-3411-4A29-969A-9BB014383279 Q24814806-92D213E6-4801-4501-B451-80C74A3B429D Q26777400-C61C88E1-A356-45EC-8D08-6E2B37F670EE Q27004659-4514E935-7AE7-494B-AF89-42A35C99CDDD Q27026428-962B990F-6E62-4AB5-9E7C-41399D4E8B01 Q27314999-73F82608-F1EE-4025-9842-125F0E206ABC Q28143405-CF7982D5-E1DA-4A0D-A6B9-886A95938290 Q28237079-385897C1-025F-4174-9993-4A3F8A0DB4DC Q28742767-B0DDB1EE-1B36-42D3-BF0A-C2E4310F9E4D Q28749067-7F427BAA-1987-4319-B58E-C9B71CEF3645 Q30638019-451B61CD-C3DC-4FF1-8C4A-5FEBDBB9B010 Q30856787-5738AB2E-AAE7-4665-9EB1-379B74DA921B Q30942866-6DDC44B7-8AAB-44BB-B59A-C2DB07120032 Q33264524-BB233A7F-FD1C-4435-BF19-990D20B5207E Q33484190-3272C4C2-3461-457B-B792-83A16B149E87 Q33543136-F580C503-4E2B-471A-AE7B-E63ED56BFB2F Q33592962-5255E141-2973-4B08-AE05-EDF54535FD46 Q33646487-65CA3070-6B27-4590-8302-09324FB3BDAE Q33653666-8ABC9DC0-C9F7-4FCF-93ED-AEDD92F34C47 Q33699974-598CB505-1730-4CF3-881A-51F4F9F8D44D Q33764576-8D41A1FA-831F-4F50-920B-822FB29BA7E2 Q33779677-0BA4CE0C-004D-4CEF-95BE-48C006077F8C Q33785337-6FA916D8-872D-49CF-B3B0-F4D9A86EBFF7 Q33869571-A7205CFC-1E86-49C5-80AA-6489B996A849 Q33881932-5DC6D9B5-C354-420A-819C-AFAD7D6FFE33 Q33972984-CB097E40-DB2B-4B8F-AAF1-BC8F0EFC5610 Q34045034-0EFEDF4D-CC1F-4D09-B354-2B459E4FCE43 Q34069427-227F6E77-9501-46DD-BC8B-5832E0C58F73 Q34084499-A2A474AF-C186-46EF-8AE9-7311E2199DD5 Q34099336-316B5DDB-F1C6-45CE-8FC8-D55717064BDC Q34111896-B059898E-E1E2-4687-95FB-C99E144284B6 Q34136951-6067EC89-65B4-4D58-BEBA-4F06A786F678 Q34233126-D516D5D8-AE75-493D-9E91-B3827CFFB49E Q34389791-B22E2EFE-46EA-4617-91F7-FB51287A7D87 Q34454532-106BC999-0A8A-4445-A899-F4E191D4F9FB Q34467240-AEC3E9F7-7E96-4881-9AAD-E766D6257FE7

P2860

Activation of nuclear factor kappa B inflammatory bowel disease.

http://www.wikidata.org/entity/Q35350256

description

1998 nî lūn-bûn

@nan

1998 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

1998 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

name

Activation of nuclear factor kappa B inflammatory bowel disease.

@ast

Activation of nuclear factor kappa B inflammatory bowel disease.

@en

type

label

Activation of nuclear factor kappa B inflammatory bowel disease.

@ast

Activation of nuclear factor kappa B inflammatory bowel disease.

@en

prefLabel

Activation of nuclear factor kappa B inflammatory bowel disease.

@ast

Activation of nuclear factor kappa B inflammatory bowel disease.

@en

P1433

Q35350256-23DE0715-4DBC-4BC1-9B1E-20D75CB52540

P1476

Q35350256-D199B796-4304-415C-AE7A-44BDAE30EDDF

P2093

Q35350256-2396781F-05C7-481D-943F-F032B1E76941

Q35350256-C4905699-F93C-4459-B72A-187AF1AE6F3D

P2860

Q35350256-0135A0F1-D5F8-417A-8680-6A623B46301E

Q35350256-05AEDBD9-8EC4-4B6A-93C8-D71B077E54DD

Q35350256-0BFEC439-718F-4463-83A4-72E3DF94DC14

Q35350256-1FF40A80-1EA9-4954-8CE4-A0857454ACCB

Q35350256-31F889B5-FF0C-43AE-A8F5-CBE86E59DAC1

Q35350256-420E0317-5EFC-4F4E-984D-636D1CAB5995

Q35350256-4497C017-1B43-4172-816B-6969E71F2A23

Q35350256-538D10FE-98E3-4DD1-9C7C-EDDA1E1CB5C2

Q35350256-566CEE63-EEE1-4684-AB85-B1B26BC94C4D

Q35350256-5E29E2DE-9F09-42DA-A58D-47984703231A

P304

Q35350256-90405966-3789-4672-9AD5-36C895BB7CBB

P31

Q35350256-6C59F935-4B74-41CC-9809-13DBEF0BEFD6

P356

Q35350256-7166FB3A-2795-4827-8136-7F91D3B1BF03

P407

Q35350256-97A2B73C-B71B-4E02-9D56-449CEA0078DC

P433

Q35350256-861332CD-AA06-4347-BF7F-21B9560CA102

P478

Q35350256-14D4AEE2-28EE-4E54-8E87-BECA70C881F1

P50

Q35350256-D5FDD1B2-B4E1-4A22-9F73-7B4FE69F7835

P577

Q35350256-4EF049BC-9B0F-4DAB-84B9-5F326F738D42

P5875

Q35350256-C1406ED5-647A-4BD1-9DC5-0778CA3B5794

P698

Q35350256-313AA433-45FE-4451-8F25-4B40A6699ACC

P921

Q35350256-5CA13FB6-3151-46AC-B684-6C22328E208F

Q35350256-757C7B86-65CD-437D-926C-2B4B10CF21E8

P932

Q35350256-FA8AAFF0-A946-4051-A6E0-40759F3C74D2

P356

P1433

P1476

Activation of nuclear factor kappa B inflammatory bowel disease.

@en

P2093

S Nikolaus

http://www.w3.org/2001/XMLSchema#string

S Schreiber

http://www.w3.org/2001/XMLSchema#string

P2860

Protein measurement with the Folin phenol reagent

The NF-kappa B and I kappa B proteins: new discoveries and insights

A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B

Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study

An interleukin-4-induced transcription factor: IL-4 Stat

Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination

NF-kappa B subunit-specific regulation of the interleukin-8 promoter

Inhibition of NF-kappa B by sodium salicylate and aspirin

Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation

NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control

P304

477-484

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUT.42.4.477

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P50

P577

1998-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13668669

http://www.w3.org/2001/XMLSchema#string

P698

9616307

http://www.w3.org/2001/XMLSchema#string

P921

inflammatory bowel diseases

P932

1727068

http://www.w3.org/2001/XMLSchema#string